Sol-Gel Provides Update Following Unblinding of Phase 1b Study of SGT-210 in Darier Disease

Core Insights - Sol-Gel Technologies, Ltd. has announced the results of its Phase 1b study of SGT-210 for Darier disease, which did not show efficacy compared to the vehicle control [2][3] - The company will not proceed with further development of SGT-210 in this indication and will focus on low-cost feasibility studies in other areas of unmet medical need [3] Company Overview - Sol-Gel Technologies is a dermatology company that develops treatments for skin diseases, including FDA-approved products like TWYNEO for acne and EPSOLAY for rosacea [5][6] - The company is currently advancing its Phase 3 clinical trial for SGT-610, a hedgehog signaling pathway blocker aimed at preventing basal cell carcinomas (BCCs) in patients with Gorlin syndrome [4][6] Product Pipeline - SGT-610 is positioned to be the first treatment for preventing BCCs in Gorlin syndrome patients, targeting the underlying genetic cause linked to the PTCH1 gene [4] - The company is also investigating SGT-210 for rare hyperkeratinization disorders, although the recent study results have halted its advancement in Darier disease [6]